A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Abstract Background Trametinib, an oral mitogen/extracellular signal-related kinase (MEK)1/2 inhibitor, holds promise for malignancies with rat sarcoma (RAS) mutations, like pancreas cancer. This phase II study was designed to determine overall survival (OS) in patients with pancreas cancer treated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2014-08, Vol.50 (12), p.2072-2081
Hauptverfasser:	Infante, Jeffrey R, Somer, Bradley G, Park, Joon Oh, Li, Chung-Pin, Scheulen, Max E, Kasubhai, Saifuddin M, Oh, Do-Youn, Liu, Yuan, Redhu, Suman, Steplewski, Klaudia, Le, Ngocdiep
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Administration, Oral Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Double-Blind Method Female Gemcitabine Hematology, Oncology and Palliative Medicine Humans Male Medical sciences MEK inhibitor Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pancreas Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - secondary Pharmacology. Drug treatments Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyridones - administration & dosage Pyrimidinones - administration & dosage Randomised Survival Analysis Trametinib Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!